Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
Xiaoning Wu(First Affiliated Hospital of Xi'an Jiaotong University), Hong You(Harbin Institute of Technology), Yameng Sun(Renji Hospital), Jilin Cheng(Beijing Ditan Hospital), Mingyi Xu(Shanghai Jiao Tong University), Yongpeng Chen(Guangxi University of Science and Technology), Qing Xie(Shanghai Jiao Tong University), Huiguo Ding(Capital Medical University), Jialing Zhou(Capital Medical University), Wen Xie(Capital Medical University), Mingxiang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuqing Zhang(Army Medical University), Wei Jiang(Sun Yat-sen University), Jun Cheng(Central South University), Shuyan Chen(Capital Medical University), Lang Bai(West China Hospital of Sichuan University), Hongxin Piao(Yanbian University Hospital), Hong Ma(Beijing Friendship Hospital), Yiwen Shi(Shanghai Normal University), Shi-Bin Xie(Third Affiliated Hospital of Guangzhou Medical University), Bingqiong Wang(Capital Medical University), Xiaojuan Ou(Capital Medical University), Jia Shang(European Foundation for the Study of Chronic Liver Failure), Anlin Ma(China-Japan Friendship Hospital), Jidong Jia(National Clinical Research Center for Digestive Diseases)
Cited by 44
Related Papers
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression
|Molecular Therapy|2010|168
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
|Hepatology|2014|165